# US 6,730,691 B1 · Uses of alpha adrenergic blocking agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,691 B1
- Document ID: US6730691B1
- Status: Granted
- Kind: B1
- Application number: 09/501,400
- Filed: 2000-02-10
- Granted: 2004-05-04
- Earliest claimed: 2000-02-10
- Inventors: Miles A. Galin
- Web page: https://patentgrep.com/patent/US6730691B1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/222: with compounds having aromatic groups, e.g. dipivefrine, ibopamine
- A61K 31/4168: having a nitrogen attached in position 2, e.g. clonidine
- A61K 31/417: Imidazole-alkylamines, e.g. histamine, phentolamine
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 27/02: Ophthalmic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are methods and compositions for inhibiting undesirable visual anomalies commonly experienced by individuals who have undergone refractive eye surgery, including photophobia, glare, secondary images and haloing. In particular, the disclosure provides for topically applying an ophthalmic solution to the eye wherein the ophthalmic solution contains a therapeutically effective amount of one or more alpha adrenergic blocking agents, preferably thymoxamine. The disclosure further provides for an ophthalmic solution containing one or more alpha adrenergic blocking agents in a physiologically acceptable carrier, which can be administered to a subject at an effective dose to be therapeutically effective in concentration and rate of release. An ophthalmic solution for inhibiting one or more visual anomalies experienced by an individual who has undergone refractive eye surgery containing a therapeutically effective amount of one or more alpha adrenergic blocking agents in combination with one or more anti-irritant agents and/or one or more anti-inflammatory agents is also disclosed.

## Claims

### Claim 1

A method of inhibiting one or more undesirable visual anomalies experienced by an individual who has undergone refractive eye surgery comprising:
topically applying an ophthalmic solution to the eye wherein the ophthalmic solution comprises a therapeutically effective amount of thymoxamine.

### Claim 2 (depends on 1)

The method of claim 1 wherein the one or more undesirable visual anomalies is selected from the group consisting of photophobia, glare, secondary images and haloing.

### Claim 3 (depends on 1)

The method of claim 1 wherein the refractive eye surgery is selected from the group consisting of surgical implantation of an intraocular lens, laser surgery and radial keratotomy.

### Claim 4 (depends on 1)

The method of claim 1 wherein the ophthalmic solution further comprises an alpha adrenergic blocking agent selected from the group consisting of phentolamine, azapetine, phenoxybenzamine, clonidine and tolazoline.

### Claim 5 (depends on 1)

The method of claim 1 wherein the ophthalmic solution is topically applied in approximately one drop dose.

### Claim 6 (depends on 5)

The method of claim 5 wherein the approximately one drop dose is topically applied on an as needed basis.

### Claim 7

An ophthalmic solution for inhibiting one or more undesirable visual anomalies experienced by an individual who has undergone refractive eye surgery comprising a therapeutically effective amount of one or more alpha adrenergic blocking agents and one or more anti-irritant agents.

### Claim 8 (depends on 7)

The ophthalmic solution of claim 7 wherein the one or more anti-irritant agents is selected from the group consisting of naphthazoline, oxymetazoline, and tetrahydrozaline.

### Claim 9 (depends on 7)

The ophthalmic solution of claim 7 wherein the concentration of the one or more anti-irritant agents is from about 0.025% to about 0.1% by weight.

### Claim 10

An ophthalmic solution for inhibiting one or more undesirable visual anomalies experienced by an individual who has undergone refractive eye surgery comprising a therapeutically effective amount of one or more alpha adrenergic blocking agents and one or more anti-inflammatory agents.

### Claim 11 (depends on 10)

The ophthalmic solution of claim 10 wherein the one or more anti-inflammatory agents is selected from the group consisting of dexamethasone, fluoromethalone, loteprednol, prednisone, and diclofenac.

### Claim 12 (depends on 10)

The ophthalmic solution of claim 10 wherein the concentration of the one or more anti-inflammatory agents is from about 0.5% to about 1% by weight.

### Claim 13

An ophthalmic solution for inhibiting one or more undesirable visual anomalies experienced by an individual who has undergone refractive eye surgery comprising a therapeutically effective amount of one or more alpha adrenergic blocking agents, one or more anti-irritant agents, and one or more anti-inflammatory agents.

### Claim 14 (depends on 13)

The ophthalmic solution of claim 13 wherein the concentration of the one or more anti-irritant agents is from about 0.025% to about 0.1% by weight and the concentration of the one or more anti-inflammatory agents is from about 0.25% to about 1% by weight.
